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Abstract
 Background—The ingestion of probiotics to attempt to improve health is increasingly 
common, however quality control of some commercial products can be limited. Clinical practice is 
shifting toward the routine use of probiotics to aid in prevention of necrotizing enterocolitis in 
premature infants, and probiotic administration to term infants is increasingly common to treat 
colic and/or prevent atopic disease. Since bifidobacteria dominate the feces of healthy breast-fed 
infants, they are often included in infant-targeted probiotics.
 Methods—We evaluated sixteen probiotic products to determine how well their label claims 
describe the species of detectable bifidobacteria in the product. Recently-developed DNA-based 
methods were used as a primary means of identification, and were confirmed using culture-based 
techniques.
 Results—We found that the contents of many bifidobacterial probiotic products differ from the 
ingredient list, sometimes at a subspecies level. Only one of the sixteen probiotics perfectly 
matched its bifidobacterial label claims in all samples tested, and both pill-to-pill and lot-to-lot 
variation were observed.
 Conclusion—Given the known differences between various bifidobacterial species and 
subspecies in metabolic capacity and colonization abilities, the prevalence of misidentified 
bifidobacteria in these products is cause for concern for those involved in clinical trials and 
consumers of probiotic products.
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 Introduction
Probiotics are dietary supplements containing non-pathogenic microbes that provide a health 
benefit to the host. A broad array of probiotics containing many different bacterial strains are 
commercially available, many of which were selected based on factors related to ease of 
production rather than identified mechanisms of protection. Well-designed studies of 
commercially available probiotics with established composition and purity are essential to 
establish safety and clinical efficacy, particularly in high-risk patients such as neonates and 
the immunocompromised. A thorough description of the components of the product is also 
crucial to understand the mechanism by which administration of a probiotic leads to 
desirable health outcomes. Factors to consider when establishing the efficacy of probiotic 
administration include the accurate identification and labeling of strains used, the viability of 
organisms administered, and consistency in product formulation over the time course of the 
study. Unfortunately, many commercial probiotics have been shown to fail at one or more of 
these criteria (1–8).
One area in which probiotics may have a strong benefit is in guiding the development of the 
microbial community of the gastrointestinal tract of the neonate. The development of the 
microbiota early in life has been shown to influence risk for susceptibility to infection and 
development of allergies and atopic disease (9,10). Perhaps the most compelling case for the 
use of probiotics is in the premature infant, where multiple randomized clinical trials have 
demonstrated a decreased risk of necrotizing enterocolitis in infants receiving probiotics 
(11,12). The hospital environment has been shown to be a likely source of inoculum for 
premature infants (13,14), and the gut microbiota of premature infants in the neonatal 
intensive care unit (NICU) was shown resemble that of NICU fomites (14). In order to 
combat this phenomenon, probiotics are increasingly administered to introduce alternative 
non-pathogenic species to colonize the gastrointestinal tract and occupy niches otherwise 
open to pathogens. Rare cases of infection from probiotic organisms or contaminants in 
premature infants underscore the importance of providing probiotic products with 
established composition and purity (15,16).
Bifidobacterium-containing products are often used in a NICU setting due to their status as 
generally recognized as safe (GRAS) microorganisms, their ubiquity in the gut of healthy 
breast-fed infants, and their observed health effects (17,18). Infants with bifidobacteria-
dominated gastrointestinal tracts have improved responses to some vaccines, higher 
resistance to colonization by some pathogens, and better gut barrier function (19–22). 
Bifidobacteria aid the proper development of the infant’s acquired and innate immune 
systems, enhancing surveillance while reducing inflammation (22–25). Comparison studies 
between strains or species of bifidobactaria are limited. In a recent study, Bifidobacterium 
longum subsp. infantis was found to be a better colonizer of the premature gut than 
Bifidobacterium animalis subsp. lactis, especially in the presence of human milk (26). This 
advantage is likely due to the capacity of B. longum subsp. infantis to consume a wide 
spectrum of human milk oligosaccharides as a direct result of the extensive array of human 
milk oligosaccharide binding, transport and degrading enzymes encoded in its genome but 
not found in many species of Bifidobacterium including B. animalis subsp. lactis (27–30). B. 
longum subsp. infantis colonization is associated with improved responses to some vaccines; 
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in addition B. longum subsp. infantis appears to decrease intestinal epithelia permeability, 
and to have anti-inflammatory effects in the premature intestine (20,22,31).
B. longum has two subspecies found in humans that historically have been challenging to 
distinguish, B. longum subsp. longum and B. longum subsp. infantis. Previous studies 
indicate B. longum subsp. longum and B. longum subsp. infantis possess different suites of 
glycolytic enzymes (27,29,32). While closely related, the two subspecies are not 
distinguishable using common methods which focus on analysis of the 16S rRNA gene 
(27,29,32,33). One commonly used probiotic product whose label lists two subspecies, B. 
longum subsp. longum and B. longum subsp. infantis, as ingredients recently reclassified the 
included strains as B. animalis subsp. lactis. This unfortunately has led to confusion, as there 
is a history of academics publishing results using this product with these strains and listing 
them as B. longum subsp. longum and B. longum subsp. infantis (34). The risk of species 
and subspecies misidentification is high, especially given the recently refined definition of 
these two B. longum subspecies through genome sequencing (27,32). Motivated by the 
potentially unfortunate consequences of species and subspecies confusion in clinical trials, 
we surveyed several Bifidobacterium-containing probiotic products to evaluate their label 
claims with regard both to these two B. longum subspecies and to other bifidobacterial 
species. To facilitate this effort, we developed a reliable and inexpensive PCR-based method 
for rapid identification of B. longum subsp. infantis at the subspecies level (20,35). To verify 
that these DNA-based methods give data that accurately reflect input DNA, we also 
validated our methods against a series of artificial mock communities.
 Results
 Method Validation Using Mock Community
We have previously developed bifidobacterial terminal restriction length polymorphism (Bif-
TRFLP) analysis to readily differentiate common bifidobacterial species and 
Bifidobacterium longum/infantis ratio analysis (BLIR) to differentiate B. longum subspecies 
(20,33). In order to evaluate commercial probiotic products we first examined if the Bif-
TRFLP/BLIR correctly differentiates a number of mock communities containing different 
combinations of bifidobacterial strain DNA. The Bif-TRFLP/BLIR results generally 
reflected the known mock communities of input DNA from common bifidobacteria probiotic 
species (Figure 1). All five tested species were observable and distinguishable from each 
other, and there was no specific bias against any species or subspecies. Communities 
containing 2, 3, 4, or 5 different strains in approximately equal levels were identified as 
containing the correct mix of strains. However, when multiple strains were present each in 
levels under 5% of total DNA, some minority strains were not observed in the output data, a 
known limitation of the TRFLP-based technique (33). Specifically, no B. animalis and B. 
breve were observed in mixture G, mixture J appeared as containing only B. breve despite 
all 5 species being added, mixture P was missing B. breve and B.bifidum, and mixtures Q 
and S were missing B. breve, B. bifidum, and B. animalis.
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 Bif-TRFLP/BLIR of Commercial Probiotics
After successful validation of the identification methods, they were used to describe the 
bifidobacterial contents of the selected probiotic products. Species observed in these 
probiotics include B. longum (both subspecies), B. bifidum, B. breve, and B animalis subsp. 
lactis. Ambiguous peaks that match both B. bifidum and B. pseudocatenulatum were 
observed, but were assumed to be B. bifidum due to the probiotic product context. The 
measured contents of the probiotic products were often consistent across both pills and lots 
(Figure 2). The analysis showed pill-to-pill variation (within a lot) in probiotic 16, and lot-
to-lot variation in probiotics 2, 10, and 11. Multiple probiotic products either contained 
unlisted species and/or did not contain the species their label claimed (Table 1). Only one 
probiotic (#5) perfectly matched its label claims in all four samples assayed, with no missing 
or additional bifidobacterial species. Amplification of bifidobacterial DNA was obtained 
from every sample except for probiotic 7 lot 2 pill 1, all probiotic 14a pills, and all probiotic 
pill 14b pills except lot 1 pill 1. It is unknown whether this represents a lack of 
bifidobacteria in the samples or potential PCR inhibitors that co-eluted with the extracted 
DNA. Attempting to reduce the concentration of potential PCR inhibitors by a 1:50 dilution 
of the genomic DNA from these failed samples, did not result in positive amplification (data 
not shown).
 Bifidobacterial Isolation
For purposes of content comparison, bifidobacterial isolates were obtained and identified (by 
MALDI Biotyper and BLIR for B. longum group isolates) from each of the probiotic 
products. Not all species listed species were isolated from the probiotics (Supplemental 
Table S1) likely a consequence of differing viability after storage, as well as differences in 
culturability. B. animalis subsp. lactis was the most commonly-isolated organism, and was 
frequently the only species isolated from the products. Indeed, B. animalis subsp. lactis was 
the only species not listed on the product labels that was found by isolation. In 3 out of 4 
cases where Bif-TRFLP found B. animalis subsp. lactis where it was not listed on the label, 
the species was also successfully isolated (Probiotics 4, 6, and 11, but not 13).
 Genome Sequencing to Confirm Results of BLIR Analysis
The BLIR method is based on unique genetic loci found in the genomes of multiple strains 
of each B. longum subspecies. Several potentially mislabeled products containing B. longum 
subsp. longum and B. longum subsp. infantis were observed using this method. To further 
confirm the results of the BLIR method, the genomes of two isolates from Product 15, where 
the label claimed B. longum subsp. infantis and BLIR indicated the contents were B. longum 
subsp. longum, were sequenced for comparison. 2.5 million reads were obtained for each 
isolate and the average genome size was 2.239 Mb. This predicted genome size is noticeably 
smaller than that of B. longum subsp. infantis ATCC 15697 (2.832 Mb) (27). Reads from the 
Product 15 isolate did not map to key loci in the B. longum subsp. infantis ATCC15697 
genome, including the subspecies-stereotypic HMO cluster described by Sela et al (27,29). 
While average read coverage for this genome was 272-fold, the average read coverage for 
the 40kb HMO cluster was zero (Supplementary Figure S1). Conversely, the Product 15 
sequence aligned well with B. longum subsp. longum DJO10A (36), indicating that the 
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Product 15 isolates were B. longum subsp. longum strains rather than the advertised B. 
longum subsp. infantis, (although strain-level differences were observed, as indicated by 
small gaps in coverage in supplemental Figure S1A). This is consistent with the 
classification given by the BLIR method.
 Discussion
Consistent with previous studies, we present further evidence that the advertised content of 
many probiotic products containing bifidobacteria vary significantly from the actual content 
(1–8). Indeed, only 1 of the 16 products tested exactly matched the bifidobacterial species 
claims on the label in every sample tested. Some products were not internally consistent as 
both pill-to-pill and lot-to-lot variation were observed. We note that many of these products 
also contained non-bifidobacterial species contents, which, for the purposes of this study, 
were not evaluated. These results suggest that quality control of probiotics is lacking. In 
order for clinical trials to provide meaningful data about the benefits of specific probiotic 
strains and enable clinicians to make informed decisions about prescribing or recommending 
probiotics, increased standards of strain identification are needed, particularly given the lack 
of regulatory oversight for certification of probiotics in the United States.
Debate continues regarding probiotic administration to premature infants, with several 
authors arguing for the routine prophylactic use of probiotics for the prevention of 
necrotizing enterocolitis (37,38). Which probiotic strain and whether a single strain or a 
combination product is superior are open questions requiring further trials. There is evidence 
supporting the use of B. longum subsp. infantis as a potential candidate species for infants, 
especially when provided in combination with breast milk (26,39). However, the current 
study shows that B. longum subsp. infantis is commonly misidentified in commercial 
probiotics, some of which are marketed towards infants. To this end, we present and validate 
potentially useful tools for evaluating probiotic contents, including a method to distinguish 
B. longum subsp. infantis from B. longum subsp. longum, a subspecies differentiation not 
possible on the basis of traditional 16S ribosomal RNA sequencing alone.
While the clear congruence between the known mock community input and resultant Bif-
TRFLP/BLIR data was encouraging from a methodological standpoint, the results from the 
products tested was concerning. There were numerous mismatches between label claims and 
our results. Probiotic 11, for example, was advertised as containing B. bifidum and B. 
longum subsp. infantis, but Bif-TRFLP/BLIR indicated its contents were B. animalis subsp. 
lactis and B. longum subsp. infantis, with some B. longum subsp. longum present in one pill. 
The second lot of Probiotic 11 had the same stock keeping unit (SKU) number as the first 
lot, was produced by the same manufacturer, and was even purchased from the same store. 
However, the product label from the second lot differed from the first lot. It now listed a B. 
animalis subsp. lactis strain (with the same trade name as the previous B. bifidum), no B. 
longum subsp. infantis, and a Lactobacillus strain. The Bif-TRFLP data from lot 2 of this 
product agrees with the new label claim, and the relabeling of the B. bifidum-named strain 
as B. animalis subsp. lactis. Such an unannounced change may or may not be noticed and 
included in the analysis of the results of a clinical trial using this product.
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Probiotic 15 was consistently listed as a containing only a B. longum subsp. infantis strain, 
while it clearly contained B. longum subsp. longum by Bif-TRFLP/BLIR. Genomic 
comparisons of two isolates from the same product lot showed it was missing large genomic 
sections present in the B. longum subsp. infantis type strain (ATCC 15697) including gene 
clusters dedicated to catabolism of human milk oligosaccharides and urea—genetic loci 
specific to the B. longum subsp. infantis subspecies (27,29). Conversely, the genome 
sequence of Product 15 aligned very closely with B. longum subsp. longum DJO10A thus 
clearly showing membership within that subspecies. Products 3, 9, and 10 also had 
misidentified B. longum subspecies contents in some samples. These results demonstrate the 
difficulty of distinguishing between these two B. longum subspecies. BLIR analysis is an 
inexpensive tool for quality control screening by clinical labs or the probiotics industry to 
rapidly differentiate B. longum product subspecies that would otherwise only be possible via 
whole genome sequencing (27) or multilocus sequence typing (29).
The contents of probiotic 6 were especially different from its labeling, as it did not appear to 
contain any of the three label species (B. longum subsp. longum, B. longum subsp. infantis, 
and B. breve) and contained two non-label species (B. bifidum and B. animalis). However 
further investigation of the Probiotic 6 label revealed a footnote indicating that the 
manufacturers reclassified both their B. longum subsp. longum and B. longum subsp. 
infantis strains as B. animalis subsp. lactis, which is in agreement with the Bif-TRFLP/BLIR 
data developed in this study. However it is unclear if such subtle footnoted-label changes, in 
lieu of actual relabeling, will be fully understood and recognized by clinicians and 
consumers.
While our use of the Bif-TRFLP and BLIR techniques has revealed numerous 
inconsistencies of product labeling with product contents, there are limitations to the 
methods used in this study. It is possible for a mutation causing an rRNA gene restriction 
site to change a cognate Bif-TRFLP fragment length and cause an incorrect (or unknown) 
species identification. In addition, while our terminal restriction fragment database is 
extensive, it does not contain every known bifidobacterial strain. Moreover, in products 
containing a mixture of strains, one strain might be present but not detected due to it being 
below the limit of detection in a mixed community, a known limitation of the technique (33). 
The absence of any detectable bifidobacterial amplicon in some samples was concerning, 
however, the possibility remains that there may have been PCR inhibitors in the sample 
which resulted in a false negative.
In conclusion, the state of species and subspecies quality control for many bifidobacteria-
containing probiotic products remains inconsistent. In our study, we found that probiotic 
products often do not correctly identify the bifidobacterial species they list on their labels. 
Probiotic products can shift their contents over time without warning, even while keeping 
the same SKU. Differentiating the two subspecies B. longum subsp. longum from B. longum 
subsp. infantis appeared to be of particular difficulty.
Clinicians face a number of challenges when administering probiotics to patients. While not 
addressed in our study, the issues of strain viability upon dosing and potential contamination 
by adventitous microorganisms (and even pathogens) are also concerns for those planning 
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clinical trials. Despite the GRAS (generally recognized as safe) status of probiotic 
supplements, the strain identity issues discussed here must be taken into account when 
planning and conducting clinical trials to ensure the proper interpretation the data generated. 
Misidentified probiotics are not likely to pose a danger to patients, however they certainly 
cloud clinic trial interpretations and are particularly problematic when the properties 
possessed by one strain are confused with another. Indeed, the use of appropriate tools (such 
as those described here) to distinguish between closely related strains such as B. longum 
subsp. longum and B. longum subsp. infantis is needed to discriminate between these 
microorganisms with significantly different metabolic capacities that impact colonization 
behavior and as well as host health outcomes (20,22). Close and continued monitoring of 
probiotic products is recommended, and consideration should be given to those probiotic 
products for which validated, good manufacturing practice (GMP) production is known. 
Certainly federally funded clinical trials using commercial probiotics would benefit from 
increased strain validation solely to ensure meaningful, interpretable, data is generated.
 Methods
 Construction of mock communities
Type strains of various Bifidobacterium species (B. longum subsp. infantis ATCC15697, B. 
longum subsp. longum DJO10A, B. animalis subsp. lactis ATCC27536, B. breve 
ATCC15700, and B. bifidum DSM20456) were grown in de Man Rogosa Sharpe (MRS) 
broth supplemented with 500 mg/L of L-cysteine-HCL, and DNA extraction was performed 
using the Epicentre MasterPure Gram Positive DNA Purification kit (Epicentre, Madison 
WI). DNA concentrations were determined by nanodrop spectrophotometry and adjusted to 
40 ng/ul. DNA from the various bifidobacteria was then combined in different ratios, as 
noted, to construct 20 mock community DNA pools. The final volume of DNA was adjusted 
to 15ul and diluted to a final concentration of 20ng/ul. One microliter of the resulting mix 
was used to perform Bif-TRFLP/BLIR as described below.
 Probiotic products and DNA extraction
A search was performed both online and in local Davis, CA stores for probiotics listing 
bifidobacteria as an ingredient, and 16 such products were selected for evaluation. One 
product (#14) contained two formulations in a single package that we list as 14a and 14b. 
Two separate lots of each probiotic product were purchased approximately 2 years apart. 
Probiotics 13 and 16 had been discontinued at the time of purchase for the second lot. 
Genomic DNA was extracted from either two separate pills or two 100 mg aliquots of 
powder of each probiotic product using the Masterpure Gram Positive DNA Purification Kit 
(Epicentre, Madison WI) after dilution and vortexing in 9 ml of phosphate buffered saline. 
Label claims of bifidobacterial content of each product were recorded.
 Bifidobacterial Terminal Restriction Fragment Length Polymorphism (Bif-TRFLP)
The method of Lewis et al. (33) was used to perform the Bif-TRFLP assay. Briefly, DNA 
from feces was amplified in triplicate by PCR using primers NBIF389 (5’-[HEX]-
GCCTTCGGGTTGTAAAC) and NBIF1018 REV (GACCATGCACCACCTGTG) (Table 
S1). DNA was purified using the Qiagen Qiaquick PCR purification kit (Qiagen, Valencia 
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CA) and then cut with restriction enzymes AluI and HaeIII. The resulting fragments were 
analyzed on an ABI 3100 Capillary Electrophoresis Genetic Analyzer at the UC Davis 
College of Biological Sciences Sequencing Facility and sizes were compared against the 
published database for species identification. The samples were analyzed with PeakScanner 
2.0 software (Applied Biosystems, Carlsbad, CA). Negative controls containing DNA-free 
water instead of sample DNA were included with each run.
 Bifidobacterium Longum-Infantis Ratio (BLIR)
A PCR-based assay, BLIR, was developed in order to determine which of the two human-
associated subspecies of B. longum (B. longum subsp. longum and B. longum subsp. 
infantis) were present in each sample and to gain an estimate of their relative abundance to 
each other (20). In brief, three primers (FWD_BL_BI (5-[HEX]-
AAAACGTCCATCCATCACA), REV_BL (5-ACGACCAGGTTCCACTTGAT), and 
REV_BI (5-CGCCTCAGTTCTTTAATGT)) targeting a conserved portion of the genome 
(between Blon_0424 and Blon_0425) shared by both subspecies were designed using 
multiple genome sequences of each subspecies. FWD_BL_BI is complementary to a 
sequence in both subspecies while REV_BL and REV_BI are complementary to nearby 
sequences in only B. longum and B. infantis, respectively. FWD_BL_BI and REV_BL 
amplify a fragment of the B. longum genome 145 bp in length, while FWD_BL_BI and 
REV_BI amplify a fragment of the B. infantis genome 114 bp in length, allowing 
differentiation of the amplicons.
Genomic DNA from each probiotic was amplified by PCR using 0.5 µl of 10 µM stock of 
each of the above primers, 12.5 µl GoTaq Green Master Mix (Promega), 1 µl of 25 mM 
MgCl2, 1 µl of template DNA, and 9 µl of nuclease free water. Cycling conditions were 
95°C for 2 minutes, 30 cycles of 95°C for 1 minute, 54°C for 1 minute, and 72°C for 30 
seconds, followed by a 72°C extension for 5 minutes. PCR products were purified from the 
mixture using the QIAquick PCR purification kit (Qiagen, Valencia CA) and diluted 1:10 to 
avoid off-scale peak sizes. Capillary electrophoresis and analysis of the amplicon sizes 
proceeded as with the Bif-TRFLP procedure above. A positive control of known genomic 
DNA was included with each PCR run to ensure potential amplification of both B. longum 
subsp. longum and B. longum subsp. infantis products. The percentage of peak area 
corresponding to each subspecies was multiplied by the percentage of B. longum species 
peak area from the Bif-TRFLP data to arrive at final abundances of each subspecies. 
Negative controls containing DNA-free water instead of sample DNA were included with 
each run.
 Bifidobacterial Isolations
To isolate bifidobacteria, 100 mg or one pill of each product was aseptically transferred to a 
sterile tube, diluted tenfold with sterile phosphate buffered saline (PBS) and homogenized 
by vortex. Serial dilutions were prepared in PBS and inoculated on modified BSIM agar 
(40). Modified BSIM agar was prepared by supplementing de Man Rogosa Sharpe (MRS) 
media with 13 g/L agar, 500 mg/L of L-cysteine-HCL, 20 mg/L of nalidixic acid, 50 mg/ml 
mupirocin, 50 mg/ml kanamycin, 50 mg/ml polymixin B sulfate, 100 mg/ml Iodoacetate, 
100 mg/ml 2,3,5-triphenyltetrazolium chloride. The plates were incubated for 48 hours at 
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37°C in an anaerobic chamber with an atmosphere containing approximately 5% carbon 
dioxide, 3% hydrogen, and the remainder nitrogen. Up to 10 resulting colonies from each 
sample with the appropriate colony appearance were streaked onto MRS-cysteine plates for 
purity for two passages. The resulting pure strains were grown in MRS broth supplemented 
with 0.05% L-cysteine and stored at −80°C in 50% glycerol.
 Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-
TOF MS) Identification of Isolates
Glycerol stocks of each isolate were streaked on MRS plates and incubated at 37°C for 48 h 
in anaerobic chamber. A colony from each plate was added to 300 µl nuclease free water in a 
1.5 ml tube and homogenized by vortex. Next, 900 µl of 98% ethanol was added to the tube, 
briefly vortexed, and centrifuged for 2 min at maximum speed. The supernatant was 
removed and the tubes were again centrifuged for 2 minutes. All liquid was decanted and the 
samples were left at room temperature to allow the ethanol to evaporate. Subsequently, 25 µl 
formic acid was then added to each tube and homogenized by vortex, followed by the 
addition of 25 µl acetonitrile. Samples were then centrifuged for 2 min and one µl of extract 
was placed on a MALDI target plate, left to dry at room temperature, covered with an α-
Cyano-4-hydroxycinnamic acid (HCCA) matrix and air dried. The MALDI target plate was 
then analyzed by a MALDI Biotyper (Bruker, Fremont CA) and the best database match for 
each isolate was recorded. The MALDI Biotyper was not found to reliably differentiate 
between B. longum subspecies (data not shown); accordingly BLIR was used on DNA 
extracted from an overnight MRS broth culture of each B. longum group isolate using the 
Epicentre Masterpure Gram Positive DNA Purification Kit (Epicentre, Madison WI) to 
identify each B. longum group isolate at the subspecies level.
 Genome Sequencing
Libraries of genomic DNA from each of two isolates of probiotic 15 identified by MALDI 
as members of the B. longum species were created using standard Illumina library prep and 
sequenced on an Illumina MiSeq by the UC Davis Genome Center DNA Technologies core, 
using 150 bp single read settings. Reads were mapped to the B. longum subsp. infantis 
ATCC 15697 and B. longum subsp. longum DJO10A ggenomes and visualized using CLC 
Bio software (Qiagen, Boston MA) (27,29,32). An equal number of reads were mapped to 
both genomes.
 Ethical Considerations
As no human or animal subjects were involved in this research, no ethical approval (e.g. 
Institutional Review Board) was sought.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Mock community composition and measurement. The expected values (as defined by the 
ratios of input DNA initially measured by A260) and observed values for each of the 20 
different mock communities assayed are shown here.
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Figure 2. 
Bifidobacterial composition of probiotic products by PCR-based methods. Each product was 
assayed four times, shown here in order grouped by product, lot 1 pill 1, lot 1 pill 2, lot 2 pill 
1, lot 2 pill 2. Blank plot area not between two different products indicates no amplicon was 
detected.
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